Tevogen Bio Holdings Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $42.3M
- Price
- $6.49
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 2.8K
About
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Quick stats
Shares outstanding6.5M
Computed float2.2M
Float / shares34.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001860871
Websitehttps://tevogen.com
AI Summary
AI-generated1/9
minorbullishregulatory
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Tevogen received written notice from Nasdaq on September 29, 2026, confirming it regained compliance with the $50 million minimum market value of listed securities requirement for continued listing on the Nasdaq Global Market.
This follows a September 9 notice confirming compliance with the minimum market value of publicly held shares requirement, and the company states both Nasdaq compliance matters are now closed.
The resolution removes a listing-standards overhang, though it reflects regained compliance rather than any change in the company's operating performance.
Red flags
- company previously fell below Nasdaq minimum market value and publicly held shares requirements -- signals weak market capitalization and possible dilution history